Stevanato Group SpA

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stevanato Group excels in 2022, eyes high value solutions growth

Stevanato Group's strong financial performance in 2022, driven by high value solutions and operational efficiency, sets a solid foundation for future growth.
Strategic focus on biologics and high growth markets, along with optimized capital spending, positions the company for long-term success.
Challenges in pricing management and capacity ramp-up require careful navigation, while opportunities in expanding high value solutions and market demand offer avenues for growth.
Overall, Stevanato Group's performance reflects resilience, strategic foresight, and a commitment to value creation, signaling a positive trajectory for the company.

Stevanato Group reports strong Q1 results, eyes biologics market growth

Stevanato Group's Q1 performance reflects robust revenue growth, profitability, and a strong order backlog, underpinned by strategic collaborations and market focus.
While facing challenges such as pricing pressures and market dynamics, the company is well-positioned to leverage opportunities in the biologics sector and innovative drug delivery solutions.
With a reiterated full-year revenue guidance and a focus on operational excellence, Stevanato Group demonstrates resilience and strategic foresight in navigating the evolving healthcare landscape.
Investors can find confidence in the company's performance, strategic strengths, and growth opportunities amidst the challenges and uncertainties in the market.

Stevanato Group SpA reports robust Q2 performance and eyes growth

Stevanato Group SpA's Q2 2023 earnings call highlighted strong performance, growth prospects, and strategic initiatives amidst market challenges.
The company's financial results, revenue breakdown, and guidance underscore its resilience and potential for sustained growth.
Addressing challenges like currency fluctuations and market dynamics while seizing growth opportunities will be key for Stevanato Group SpA's future success.

Stevanato Group reports strong Q3 earnings, eyes biologics market growth

Stevanato Group's Q3 2023 performance showcased robust revenue growth and margin expansion, despite challenges in specific segments. The company's strong presence in key biologics markets and strategic priorities for sustainable growth position it well for the future. Opportunities in expanding markets and a solid order backlog provide a positive outlook.

Stevanato Group reports 10% revenue growth in Q4 2023

Stevanato Group's 2023 performance reflects growth driven by high-value solutions and strong demand.
Despite challenges like margin pressure and supply chain issues, the company remains confident in achieving growth.
Opportunities lie in expanding capacity, enhancing product mix, and capitalizing on backlog growth.
The company anticipates a stronger second half of 2024 and foresees material revenue impact from biologic products in 2025.

Stevanato Group faces Q1 challenges, invests in growth opportunities

Stevanato Group's Q1 2024 performance was impacted by industry-wide challenges, but the company remains focused on strategic priorities and operational efficiencies.
Despite revenue decline and margin impacts, the company's commitment to growth through expansion projects and high-value solutions showcases resilience and forward-thinking.
Challenges in vial demand and customer delays are being addressed through cost management and strategic actions, while opportunities in new investments and operational focus are being pursued.
The company's leadership position, solid strategy, and emphasis on execution position Stevanato Group for long-term success despite near-term headwinds.

Stevanato Group reports modest revenue growth amidst margin challenges

Stevanato Group delivered mixed results in Q2, with revenue growth driven by the Biopharmaceutical and Diagnostic Solutions segment.
While facing margin pressures and operational challenges, the company's focus on high-value solutions and efficiency improvements bodes well for long-term prospects.
Navigating through current obstacles, Stevanato Group remains optimistic about its ability to drive growth and enhance profitability.

Stevanato Group adjusts guidance amidst challenges, eyes growth opportunities

Stevanato Group's Q3 2024 performance was impacted by challenges in Engineering and the U.S., leading to a revised full-year guidance.
Despite operational challenges, the company demonstrated strengths in capacity expansion, innovation, and revenue growth.
Addressing challenges in vial destocking and segment optimization presents opportunities for future growth and profitability.
Analyst questions highlighted the need to navigate current challenges while capitalizing on opportunities for strategic advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva™, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies. Vertiva™'s unique design consists of a single-use pod with a pre-fi.

Stevanato Group Presents Vertiva™, a Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies and for Large Delivery Volumes (up to 10mL)

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7.

Stevanato Group Announces Change in Ex-Dividend Date for its Dividend

Stevanato Group S.p.A. (NYSE:STVN ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Lisa Miles - Senior Vice President, Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Lago - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Paul Knight - KeyBanc Capital Markets Tim Daley - Wells Fargo Dave Windley - Jefferies John Sourbeer - UBS Operator Good afternoon.

Stevanato Group S.p.A. (STVN) Q1 2023 Earnings Call Transcript

First Trust International Equity Opportunities ETF

Goldman Sachs Future Health Care Equity ETF

Growth stock Stevanato plunged after first quarter earnings as sales from Covid related services fell; maintained its full year outlook The post As Covid Wanes, Maker Of Glass Vials, Other Medical Products Misses Estimates appeared first on Investor's Business Daily.

As Covid Wanes, Maker Of Glass Vials, Other Medical Products Misses Estimates

Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.12 per share a year ago.

Stevanato Group (STVN) Q1 Earnings Lag Estimates

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2023, and maintained its fiscal 2023 guidance. First Quarter 2023 Highlights (compared with the same period last year) First quarter revenue increased 12% to €238 million. Revenue from high value solutions.

Stevanato Group Reports First Quarter 2023 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the upcoming BofA Securities Healthcare Conference at the Encore hotel in Las Vegas that will take place from May 9, 2023 to May 11, 2023. The Company will present on Tuesday, May 9, 2023 at 9:20 a.m. PT. A live audio webcas.

Stevanato Group to Present at BofA Securities Healthcare Conference

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?

Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Stevanato Group S.p.A. (STVN) Hit a 52 Week High, Can the Run Continue?

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m.

Stevanato Group to Report First Quarter 2023 Financial Results on May 4, 2023

Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today its collaboration with Thermo Fisher Scientific, the world leader in serving science, to bring to the market a fully integrated on-body delivery system platform for subcutaneous administration.

Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with leading Contract Development and Manufacturing Organisation (CDMO), Recipharm.

Stevanato Group Collaborates with Recipharm to Develop and Manufacture Pre-fillable Syringes for Use in a New Soft Mist Inhaler for the Inhalation of Sensitive Biological Products

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum taking place on March 21 and March 22, 2023. The Company will present on Tuesday, March 21, 2023 at 11:15 a.m. ET.

Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced two separate agreements with BNL BNP Paribas and Cassa Depositi e Prestiti Group (CDP) to obtain ESG-linked funds to support its ongoing global expansion.

Stevanato Group Secures €130 Million ESG-Linked Financing From BNL BNP Paribas and Cassa Depositi e Prestiti to Support Sustainable Global Growth

Stevanato (STVN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Stevanato (STVN) Stock

Stevanato Group S.p.A. (NYSE:STVN ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Lisa Miles - SVP Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Patrick Donnelly - Citi Derik De Bruin - Bank of America Tim Daley - Wells Fargo John Sourbeer - UBS David Windley - Jefferies Madeline Mollman - William Blair Drew Ranieri - Morgan Stanley Operator Good afternoon.

Stevanato Group S.p.A. (STVN) Q4 2022 Earnings Call Transcript

Stevanato (STVN) delivered earnings and revenue surprises of 18.75% and 9.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2022, and established fiscal 2023 guidance. Fourth Quarter and Full Year 2022 Highlights (compared with the same periods last year) Fourth quarter revenue increased 26% to €292.

Stevanato Group Reports Fourth Quarter and Fiscal Year 2022 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2022 on Thursday, March 2, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m.

Stevanato Group to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 2, 2023

PIOMBINO DESE, Italy--( BUSINESS WIRE )--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its latest collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company. The collaboration will enable Stevanato Group to add cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) PFS to its existing portfolio of solutions providing added value in the customers' supply chain.

Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma

Stevanato Group S.p.A. (NYSE:STVN ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Lisa Miles - SVP Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Elizabeth Speyer - Citigroup Inc. Derik De Bruin - Bank of America Paul Knight - KeyBanc Capital Markets David Windley - Jefferies Madeline Mollman - William Blair Timothy Daley - Wells Fargo John Sourbeer - UBS Operator Good afternoon.

Stevanato Group S.p.A. (STVN) Q3 2022 Earnings Call Transcript

PIOMBINO DESE, Italy--( BUSINESS WIRE )--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Jefferies London Healthcare Conference at 12:55 p.m. (GMT) on November 17, 2022.

Stevanato Group to Present at Upcoming Investor Conference

Stevanato (STVN) delivered earnings and revenue surprises of 7.69% and 0.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A.

News for Stevanato Group SpA Stock (STVN)